Vertex Pharmaceuticals Intrinsic value of stock options exercised remained flat by 0.0% to $36.95M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 31.0%, from $28.20M to $36.95M. Over 2 years (FY 2023 to FY 2025), Intrinsic value of stock options exercised shows an upward trend with a 7.3% CAGR.
High intrinsic value realized suggests strong stock performance and significant compensation payout to employees.
The total intrinsic value realized by employees upon the exercise of their stock options during the period. Intrinsic va...
Standard disclosure for companies with significant stock option programs.
other_share_based_compensation_arrangement_by_share_base_f4d743| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $128.40M | $112.80M | $147.80M |
| YoY Change | — | -12.1% | +31.0% |